bioRxiv preprint doi: https://doi.org/10.1101/2020.06.27.175281; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Small molecules exploiting structural differences within microRNA-200 precursors family members reverse a type 2 diabetes phenotype Hafeez S. Haniffa,1, Xiaohui Liua,1, Laurent Knerrb, Malin Lemurellb, Daniel Abegga, Alexander Adibekiana, and Matthew D. Disneya,2 a The Scripps Research Institute, Department of Chemistry, 130 Scripps Way, Jupiter, FL 33458, USA b Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Pepparedsleden, 1, SE-431 83 Mölndal, Sweden 1 These authors contributed equally to this work. 2 Author to whom correspondence should be addressed Email:
[email protected] Classification: Major: Biological Science; Minor: Biochemistry 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.27.175281; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract MicroRNA families are pervasive in the human transcriptome, but specific targeting of individual members is a challenge because of sequence homology. Many of the secondary structures of the precursors to these miRs (pre-miRs), however, are quite different.